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The anatomical spread of lymph node (LN) metastasis is of practical importance in 
the surgical management of colon cancer (CC). We examined the effect of KRAS, 
BRAF, and microsatellite instability (MSI) on LN count and anatomical spread pat-
tern in stage III CC. We determined KRAS, BRAF, and MSI status from stage III CC 
patients. Biomarker status was correlated with LN count and anatomical spread 
pattern, which was classified as sequential or skipped. Relapse- free survival (RFS) 
was estimated using Kaplan- Meier method, and correlations were assessed using 
log- rank and Cox regression analyses. We analyzed 369 stage III CC patients. The 
proportion of KRAS mutant (mt), BRAF mt, and MSI- high (H) were 44.2% (163/344), 
6.8% (25/344), and 6.8% (25/344), respectively. The mean number of metastatic 
LN was higher in microsatellite- stable (MSS) compared with MSI patients (3.5 vs. 
2.7, P = .0406), although no differences were observed in accordance with KRAS 
or BRAF status. Interestingly, patients with BRAF mt and MSI- H were less likely to 
harbor skipped metastatic LN (9.3% vs 20% and 4% vs 10.5% compared with BRAF 
wild- type (wt) and MSS, respectively), but KRAS status did not predict anatomical 
spread pattern. Patients with KRAS wt and MSI- H showed superior RFS compared 
with KRAS mt and MSS patients, respectively, whereas BRAF status did not affect 
RFS. Differences exist in the anatomical pattern of invaded LN in accordance with 
the molecular status of stage III CC. Patients with MSI- H CC have less invaded and 
skipped LN, suggesting that a tailored surgical approach is possible.
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1  | INTRODUC TION
Colorectal cancer (CRC) is the third most common cancer world-
wide, and accounts for approximately 1.7 million cases and 700 000 
deaths per year.1 Over the past few years, the treatment of meta-
static CRC has been personalized based on molecular and biologi-
cal factors. In patients with RAS wild- type (wt) CRC, anti- epidermal 
growth factor receptor (anti- EGFR) therapy has been used2,3 and 
immune checkpoint inhibitors such as anti- PD- 1 and anti- PDL- 1 an-
tibodies are effective in microsatellite instable (MSI- high) patients.4 
Recently, the efficacy of encorafenib, binimetinib, and cetuximab for 
BRAF mutant (mt) CRC was confirmed in a phase III trial.5 However, 
current surgical treatment of stage III CRC does not incorporate the 
status of these molecular biomarkers.
Colon cancer spreads along hematogenous and lymphatic path-
ways, but the exact clinical relevance and anatomical pathways of 
lymphatic spread in CC are incompletely elucidated.6- 9 We previ-
ously reported that the anatomical pattern of lymphatic spread, and 
its prognostic implications, differed between right and left colon 
cancer.8,9 Whether molecular biomarkers such as KRAS, BRAF and 
MSI status correlate with the extent and anatomical pattern of LN 
metastasis in stage III CC is currently unknown.10,11 Insight into 
these relationships may allow tailoring of the surgical approach, and 
the extent of lymphadenectomy, based on the molecular status of 
the tumor.
Here, we investigated whether KRAS, BRAF, and MSI status 
were related to the extent of nodal involvement, the anatomical pat-
tern of lymphatic spread, and RFS in a cohort of stage III CC patients 
who underwent extensive lymphadenectomy.
2  | METHODS
2.1 | Patient selection
Data from pathological stage III CC patients from 4 specialized 
centers (Hyogo College of Medicine, Nippon Medical University 
Hospital, Kanagawa Cancer Center and Shimane Prefectural Central 
Hospital) who were treated between 2012 and 2018 were collected 
retrospectively. The patients were all treated with extensive lym-
phadenectomy (Japanese D3 dissection) and achieved a pathological 
R0 resection. The 7th edition of the UICC TNM classification was 
used.12 Patients treated with neoadjuvant treatment and patients 
with rectal cancer were excluded. This retrospective study was ap-
proved by the Institutional Review Board of Hyogo College of medi-
cine, Japan (N0. 3445).
2.2 | Surgical treatment/chemotherapy
Open or laparoscopic colonic resection with Japanese D3 LN dis-
section was performed in all patients. For right- sided cancers, 
central vascular ligation was performed, removing draining LNs 
(stations 203, 213, and 223) along the superior mesenteric vein. 
For left- sided cancer, either high ligation of the inferior mesen-
teric artery was performed, with removal of LNs at station 253, or 
the left colic artery was preserved, and the superior rectal artery 
divided at its origin. This technique is theoretically similar to CME 
with CVL.13,14 Adjuvant therapy was administered based on local 
practice.
2.3 | Definition of LN spreading pattern and L level
According to the Japanese Society for Cancer of the Colon and 
Rectum (JSCCR), invaded LNs were classified into 3 groups, as car-
ried out in our previous studies: 8,9 L1 (paracolic), L2 (intermediate) 
and L3 (main or central) (Figure 1). The anatomical pattern of meta-
static LN spread was classified as sequential when a positive (cancer 
invaded) LN occurred only when all previous LN stations were posi-
tive, and as skipped whenever a positive LN was identified with 1 or 
more previous nodal stations (L1 and/or L2) negative.
2.4 | Mutational analysis of KRAS and BRAF, and 
assessment of MSI
Colorectal cancer specimens and the adjacent normal tissues for com-
parison were retrospectively collected from patients who had under-
gone surgery. All protocols were approved by the ethics committee of 
Hyogo College of Medicine as RINHI- 0120 and all patients provided 
written informed consent. These specimens were stored in RNAlater 
at −80°C before use. Genomic DNA was extracted using the QIAamp 
DNA mini kit (Qiagen, Venlo, Netherlands). Genomic DNA was used to 
evaluate their microsatellite instability (MSI) status. The mononucleo-
tide microsatellite markers BAT- 25, BAT- 26, NR21, NR22, and NR24 
were used for evaluation as previously described.15 We also analyzed 
the mutations of KRAS codon 12, KRAS codon 13, and BRAF codon 
600 using Sanger sequencing. All analyses were performed at the 
Hyogo College of Medicine and Nippon Medical School Hospital.
2.5 | Statistical analysis
The chi- square or Fisher exact test was used to evaluate differ-
ences between proportions, and Student t test or Mann- Whitney U 
test was used to evaluate differences between means, as appropri-
ate. RFS were estimated from the date of surgery until recurrence 
or death from any cause. The Kaplan- Meier method and log- rank 
test were used for survival analysis. Multivariate Cox proportional 
hazards regression was used to identify independent prognostic 
variables. The presence of pathological lymphatic invasion and ve-
nous invasion was classified in accordance with the JSCCR system: 
0; no invasion, 1; mild invasion, 2; moderate invasion, and 3; severe 
invasion.16 Pathological lymphatic and venous invasions were ana-
lyzed as categorical covariates. All analyses were performed with 
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IBM® SPSS® Statistics, version 25. P- values were reported and in-
terpreted in accordance with recent guidelines from the American 
Statistical Association.17
3  | RESULTS
In total, data from 369 stage III CC patients were collected and ana-
lyzed. The median follow- up time was 53 mo. Patient characteris-
tics are shown in Table 1. The proportion of KRAS mt, BRAF mt, 
and MSI- H patients was 44.2% (163/206), 6.8% (25/344), and 6.8% 
(25/344), respectively. The proportion of BRAF mt and MSI- H in 
each anatomical location was different from that of BRAF wt and 
MSI- H, respectively (BRAF; P = .00735, MSI; P = .0306) but there 
was no difference regarding KRAS (P = .524). The mean number of 
harvested LN was lower in BRAF mt compared with BRAF wt pa-
tients (20.0 vs. 24.8; P = .0360), but the mean number of invaded 
LN did not differ based on BRAF status. Conversely, MSI status did 
not affect the number of harvested LN (23.3 vs. 24.6 in MSI- H and 
MSS, respectively; P = .626), but the mean number of invaded LN 
was higher in MSS patients (3.5 vs 2.7; P = .0410). The incidence of 
central LN positive (L3) disease was similar regardless of biomarker 
status. Adjuvant therapy was given to 260/369 patients (70.5%); 90 
of these patients (24.4%) received doublet chemotherapy such as 
mFOLFOX6 or CapOX.
The anatomical pattern of LN metastasis is shown in Table 2. 
Mutational status of KRAS did not affect the proportion of patients 
with skipped LN metastases (9.8% in KRAS mt and 10.2% skipped in 
KRAS wt). However, the proportion of BRAF mt and MSI- H patients 
with a skipped lymphatic spread pattern tended to be lower com-
pared with that of BRAF wt and MSS, (9.3% vs 20%; P = .0901 and 
4% vs 10.5%, P = .259, respectively).
Survival based on biomarker status is shown in Figure 2. KRAS 
wt patients showed better RFS (Figure 2A; P = .02), but BRAF status 
did not affect RFS (Figure 2B; P = .65). MSI- H patients showed a 
better RFS compared with MSS (Figure 2C; P = .007). In a Cox mul-
tivariate model, the total number of LN invaded, KRAS mt, patho-
logical venous invasion, elevated carcinoembryonic antigen (CEA) 
levels before surgery, and a skipped LN pattern were identified as 
poor prognostic factors. Overall, RFS of patients with a sequential 
metastatic LN pattern tended to be better compared with patients 
with a skipped pattern (Figure 3A; P = .086). No survival difference 
F I G U R E  1   A, Anatomical LN stations 
in accordance with the JSCCR. B, Route 
of the lymphatic metastasis is described 
in this schema. The Halsted model 
(green dotted arrows) assumes stepwise 
progression from the primary tumor 
over L1→L2→L3 nodes and ultimately to 
distant organs. The Fisher model (yellow 
dotted lines), conversely, the presupposes 
that spread of metastatic tumor cells 
occurs early and to paracolic nodes, 
central nodes, or metastatic sites in a 
random manner. T, tumor; M, metastasis
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TA B L E  1   Patient characteristics













N = 25 P
Gender (%)
Male 188 (51.0) 110 (53.4) 71 (43.6) .0745 170 (49.4) 11 (44.0) .681 173 (50.3) 8 (32.0) .0974
Female 181 (49.0) 96 (46.6) 92 (56.4) 174 (51.6) 14 (56.0) 171 (49.7) 17 (68.0)
Age
Mean 68.7 68.8 68.6 .859 68.3 74.0 .0190 68.4 72.1 .196
Tumor size (mm)
Mean 47.0 46.7 47.4 .851 46.9 48.3 .339 46.9 48.5 .205
Anatomical location (%)
C 41 (11.1) 18 (8.7) 23 (14.1) .524 34 (9.8) 7 (28.0) .00735 36 (10.4) 5 (20.0) .0306
A 76 (20.5) 39 (18.9) 37 (22.7) 68 (19.7) 8 (32.0) 67 (19.4) 9 (36.0)
T 42 (11.3) 25 (12.1) 17 (10.4) 38 (11) 4 (16.0) 37 (10.7) 5 (20.0)
D 22 (5.9) 13 (6.3) 9 (5.5) 20 (5.8) 2 (8.0) 21 (6.1) 1 (4.0)
S 112 (30.3) 67 (32.5) 45 (27.6) 109 (31.6) 3 (12.0) 108 (31.3) 4 (16.0)
Rs 76 (20.9) 44 (27.8) 32 (19.7) 75 (22.1) 1 (4.0) 75 (22.1) 1 (4.0)
T stage (%)
T1 8 (2.2) 7 (3.3) 1 (0.6) .0399 7 (2) 1 (4) .745 8 (2.3) 0 (0) .744
T2 19 (5.1) 13 (6.3) 6 (3.6) 17 (4.9) 2 (8) 17 (4.9) 2 (8)
T3 222 (60.2) 129 (62.6) 93 (57) 209 (60.8) 13 (52) 206 (59.9) 16 (64)
T4 120 (32.5) 57 (27.8) 63 (38.8) 111 (32.3) 9 (36) 113 (32.9) 7 (28)
N stage (%)
N1a 130 (35.2) 71 (34.4) 59 (36.1) .778 125 (36.3) 5 (20) 0.103 120 (34.9) 10 (40) .609
N1b 119 (32.2) 64 (31) 55 (33.7) 108 (31.4) 11 (44) 111 (32.3) 8 (32)
N2a 75 (20.3) 43 (20.8) 32 (19.6) 67 (19.5) 8 (32) 69 (20.1) 6 (24)
N2b 45 (12.3) 28 (13.8) 17 (10.6) 44 (12.5) 1 (4) 44 (12.7) 1 (4)
Lymphatic invasion score (%)
0 64 (17.3) 32 (15.5) 32 (19.6) .496 63 (18.3) 1 (4) .00959 62 (18) 2 (8) .0143
1 178 (48.2) 97 (47) 81 (49.6) 170 (49.4) 8 (32) 170 (49.4) 8 (32)
2 86 (23.3) 51 (24.7) 35 (21.4) 76 (22.1) 10 (40) 78 (22.7) 8 (32)
3 41 (11.2) 26 (12.8) 15 (9.4) 35 (10.2) 6 (24) 34 (9.9) 7 (28)
Venous invasion score (%)
0 67 (18.2) 32 (15.5) 35 (21.4) .438 64 (18.6) 3 (12) .716 65 (18.9) 2 (8) .111
1 170 (46.1) 99 (48) 71 (43.5) 156 (45.3) 14 (56) 153 (44) 17 (68)
2 90 (24.4) 53 (25.7) 37 (22.6) 85 (25) 5 (20) 87 (25.3) 3 (12)
3 42 (11.3) 22 (10.8) 20 (12.5) 39 (36.1) 3 (12) 39 (11.8) 3 (12)
Number of LN (mean)
Harvested 24.5 24.1 25.0 .536 24.8 20.0 .0360 24.6 23.3 .626
Positive 3.5 3.5 3.4 .825 3.5 3.3 .969 3.5 2.7 .0410
Positive anatomical LN level (L group; %)
L1 245 (66.4) 128 (62.1) 117 (71.8) .139 230 (66.9) 15 (60.0) .175 226 (65.7) 19 (76.0) .558
L2 89 (24.1) 55 (26.7) 34 (20.9) 84 (24.4) 5 (20.0) 85 (24.7) 4 (16.0)
L3 35 (9.5) 23 (11.2) 12 (7.3%) 30 (8.7) 5 (20.0) 33 (9.6) 2 (8.0)
Bold values indicate P < .05 is considered as significant.
     |  5JIHYUNG et al
was observed between the sequential and skipped patterns in KRAS 
wt patients (Figure 3B; P = .82). Conversely, RFS of KRAS mt pa-
tients with a sequential pattern was better compared with those 
with a skipped pattern (Figure 3C; P = .018). Univariate analysis of 
RFS based on the maximal level of LN invasion showed a significant 
difference in RFS between L1, L2, and L3 (Figure 4A; P < .001). This 
difference remained unchanged after correction for KRAS status in 
a Cox model (Figure 4B; Table 3).
Subgroup analysis based on tumor sidedness in KRAS wt and 
KRAS mt CC patients showed that in left- sided CC, RFS of KRAS 
mt patients with a sequential pattern were better compared with 
those with a skipped pattern (Figure 5A (wt), P = .34 in left- sided 
and Figure 5B (wt), P = .43 in right- sided; Figure 5C (mt), P = .001 
in left- sided and Figure 5D (mt) P = .51 in right- sided). Regarding 
BRAF, tumor sidedness, and LN skip pattern did not affect RFS. In 
MSS patients, RFS with a sequential anatomical spread pattern was 
better compared with those with a skipped pattern (P = .018), but 
there was no association of LN spread pattern with RFS in MSI- H 
patients (P = .818).
4  | DISCUSSION
Although the anatomical pathways of lymphatic spread in CC have 
been discussed for several decades, the exact mechanisms are 
not fully understood. Historically, 2 theoretical models have been 
advocated (Figure 1). In the Halsted model, lymphatic spread is a 
stepwise, orderly process in which cancer cells spread from the 
primary tumor to nearby LNs, then to intermediate nodes, subse-
quently to central nodes, and finally to distant organs such as the 
liver.18 The Halsted model is based on the assumptions that lym-
phatic progression can only arise when the previous LN station is 
breached, and that resection of all invaded nodes may result in a 
cure. Conversely, in the Fisher model, lymphatic as well as hema-
togenous metastasis occur early, and at random.19 When the Fisher 
model would apply to CC, extensive surgery to retrieve all invaded 
LN is unlikely to affect outcome. Recently, several phylogenetic 
analyses on a limited number of patients indicated that metastasis 
to distant organs and lymphatic spread occurred simultaneously in 
CC.20- 22 We have previously reported the patterns of LN spread 
in stage III CC, but molecular data were not incorporated.8,20 It 
is likely that the temporal and anatomical patterns of lymphatic 
spread are governed by the molecular and genetic properties of 
the primary cancer. This is the first analysis of the association be-
tween the anatomical pattern of LN spread and selected molecular 
biomarkers in CC.
The results of the present study confirmed that the pattern of 
LN metastasis in stage III CC is related to biomolecular properties. 
First, we found striking differences in the proportion of patients 
with a skipped metastatic pattern in accordance with MSI and 
BRAF status. In the entire cohort, the proportion of patients with 
a skipped metastatic LN pattern was comparable with previous 
studies, ranging between 0% and 18%.8,9,23 Patients with a defi-
cient mismatch repair had a much lower proportion of skipped LN 
stations (4% vs 10.5%), although this difference was not statistically 
significant due to the relatively small number of MSI- H patients. 
Previous studies have shown that mismatch repair deficient tumors 
are characterized by extensive infiltration by activated T- cells.24- 30 
Little information is known on the effect of mismatch repair (MMR) 
status on the microenvironment of locoregional LN. One study 
found that, compared with MSS, LN from MSI- H tumors tended 
to have more follicular hyperplasia and very prominent paracorti-
cal hyperplasia.31 As the paracortex is a T cell zone, this phenotype 
may reflect regional infiltration of T lymphocytes, which may pre-
vent metastatic cells to effectively transfer node station and cause 
a skipped metastatic LN pattern. Similarly, we found that patients 
harboring a BRAF mutation were significantly less likely to display 
a skipped metastatic nodal pattern (9.3% vs 20%). This finding may 
be related to the fact that a subset of patients with BRAF mutations 
is known to display a high stromal CD8- positive cell infiltration and 
Invaded LN pattern 
(L1L2L3)
KRAS BRAF MSI




+−− 71.8 62.1 60.0 66.9 65.7 76.0
++− 14.1 20.4 12.0 18 18 16.0
+++ 4.3 7.3 8.0 5.8 5.8 4.0
Total 90.2 89.8 80.0 90.7 89.5 96.0
Skipped (%)
−+− 0.0 1.0 4.0 0.3 0.6 0.0
+−+ 0.6 1.0 0.0 0.9 0.9 0.0
−−+ 6.7 6.3 8.0 6.4 6.7 4.0
−++ 2.5 1.9 8.0 1.7 2.3 0.0
Subtotal 9.8 10.2 20.0 9.3 10.5 4.0
TA B L E  2   The anatomical pattern of LN 
metastasis and molecular status
6  |     JIHYUNG et al
to have a prognosis that is similar to wt patients. This is supported 
by the fact that we did not find a survival difference in accordance 
with BRAF mutational status, in contrast with other published re-
ports. Therefore, our findings may not be applicable to all patients 
with a BRAF mutation.
In addition, we found that the total number of invaded LN in 
MSI- H patients was lower compared with those with MSS tumors. 
Belt et al have reported that a higher number of LN harvested was 
associated with MSI status but the association of the number of 
LN invaded with MSI status was not mentioned.32 In our study, the 
F I G U R E  2   Unadjusted RFS in CC 
patients with; KRAS wt vs. KRAS mt (A; 
KRAS wt = red, KRAS mt = blue), BRAF 
wt vs. mt (B; BRAF wt = red, BRAF 
mt = blue), MSS vs. MSI- H (MSS = red, 
MSI- H = blue)
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number of LN harvested is similar in MSS and MSI- H tumors. We 
have also advocated the prognostic significance of positive cen-
tral lymph node (L3) in our previous studies.8 In our series, there 
are only 2 MSI- H patients with invaded central LN, following a 
sequential pattern, and no recurrence was observed. Although the 
sample size is small, these findings suggest that MSI- H patients may 
benefit more from extensive lymphadenectomy compared with 
MSS patients.
F I G U R E  3   A, RFS in CC patients 
with sequential vs. skipped LN pattern 
(sequential = blue, skipped = red). B, RFS 
in KRAS wt CC patients with sequential 
vs. skipped LN pattern (sequential = blue, 
skipped = red). C, RFS in KRAS mt CC 
patients with sequential vs. skipped LN 
pattern (sequential = blue, skipped = red)
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Regarding the impact of LN spread pattern and biological sta-
tus on survival, RFS of CC patients with a sequential spread pat-
tern was longer compared with those with a skipped pattern. In 
subgroup analysis based on KRAS status, there was no difference 
in RFS among KRAS wt CC patients between sequential pattern 
and skipped patterns. However, in KRAS mt patients, RFS of pa-
tients with a sequential pattern was longer compared with those 
with a skipped pattern. When patients were classified based on 
the location of invaded LN (L1, L2, L3), KRAS status did affect the 
survival outcome in each L group. When patients were divided into 
right vs left colon cancer, RFS was shorter in left- sided KRAS mt 
CC with a skipped pattern, but no difference in RFS was observed 
in right- sided KRAS mt CC with a skipped pattern. Large cohort 
analysis showed that RFS was longer in left- sided compared with 
in right- sided stage III CC.33 Guinney et al proposed CMS, by which 
colorectal cancer was classified into 4 molecular subtypes. CMS3 
is characterized by frequent KRAS mutations, chromosomal in-
stability, and marked WNT and MYC signaling activation.34 CMS1 
encompasses the majority of MSI tumors, including hypermutated 
and hypermethylated subtypes. From the combined analysis of 
CALGB/SWOG80405 and FIRE- 3 carried out by Aderka et al, 
overall survival of patients with CMS3, which accounted for 13% 
of all the left- sided CC, was worse compared with that of patients 
with CMS2 and CMS4, which accounted for 78%.35 Further analy-
sis using other gene mutations may help to clarify the mechanism 
to cause skip metastases of LN.
The survival benefit of adjuvant chemotherapy in stage III CC 
patients with MSI- H is still under discussion.36 The pooled analy-
sis of 2 phase III trials (NCCTG N0147 and PETACC8) indicated a 
small survival benefit of adjuvant FOLFOX in MSI- H tumors.37 The 
pooled data of the IDEA collaboration showed that almost half of 
the patients who received 6 mo of FOLFOX or CapOx chemother-
apy experienced grade 2 or greater neurotoxicity.38 As the benefit 
of 5- FU monotherapy seems small in stage III CC with MSI- H from 
the pooled analysis of 5 RCTS,39 short cycles of FOLFOX or CapOx 
until the onset of severe neurotoxicity can be an option for this 
population.
There are several limitations and uncertainties in our study. 
First, this is a retrospective study and the sample size of MSI- H 
and BRAF mt patients was small. Additionally, RFS is comparatively 
F I G U R E  4   A, RFS among each L group 
(L1, L2, and L3). B, RFS among each L 
group (L1, L2, and L3) adjusting for KRAS 
status
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high with few events, therefore statistical power of the analyses 
was limited. As measurement of MSI- H and BRAF mt for stage III 
CC is now covered by health insurance, future larger scale studies 
can be foreseen. Second, NRAS status was lacking in 171/369 
patients, therefore analysis stratified into NRAS status was not 
performed. Third, the definition of “skipped” and “sequential” was 
based on the distribution pattern of LN invaded, which was just 
evaluated microscopically using 1 slice of the specimen. Yamamoto 
et al evaluated the presence of micrometastases in negative LN, 
evaluating CEA mRNA extracted from these LNs by RT- PCR.40 In 
total 24% of the stage II CC patients were CEA mRNA positive, 
indicating possible micrometastases in negative LN. Our group 
is now planning the re- evaluation of LN spreading pattern using 
OSNA.41
In conclusion, the pattern of invaded LN varies in accordance 
with molecular status. ‘skipped’ LN metastases were twice as fre-
quent in BRAF wt and MSS tumors, compared with BRAF mt and 
MSI tumors. Less intensive treatment strategies, including less ex-
tensive lymphadenectomy, may be an option in MSI- H CC because 
the LN spread pattern is mostly sequential, and less LN are usually 
invaded. Further studies in larger datasets are warranted to confirm 
our findings.
ACKNOWLEDG MENTS
Wim Ceelen is a senior clinical investigator from the Fund for 
Scientific Research – Flanders (FWO).
CONFLIC T OF INTERE S T
The authors have no conflicts of interest to disclose.
F I G U R E  5   A, RFS of KRAS wt patients based on tumor sidedness (left colon; sequential = blue, skipped = red). B, RFS of KRAS wt 
patients based on tumor sidedness (right colon; sequential = blue, skipped = red). C, RFS of KRAS mt patients based on tumor sidedness (left 
colon; sequential = blue, skipped = red). D, RFS of KRAS mt patients based on tumor sidedness (right colon; sequential = blue, skipped = red)
TA B L E  3   Cox multivariate model for RFS
Variable P value Hazard ratio
95%CI
Lower Upper
Total LN invaded .001 1.071 1.027 1.117
KRAS .038 1.555 1.025 2.358
BRAF .765 0.879 0.380 2.038
Pathological lymphatic invasion
0 .430 1
1 .926 0.960 0.411 2.244
2 .955 0.981 0.508 1.896
3 .308 1.408 0.729 2.719
Pathological venous invasion
0 .036 1
1 .030 0.418 0.190 0.917
2 .015 0.484 0.270 0.868
3 .380 0.770 0.429 1.381
Elevated pre- Op 
CEA
<.001 1.001 1.000 1.001
Skipped .020 0.516 0.296 0.899
Bold values indicate P < .05 is considered as significant.
10  |     JIHYUNG et al
ORCID
Kozo Kataoka  https://orcid.org/0000-0003-2043-8184 
Takeshi Yamada  https://orcid.org/0000-0002-1436-7482 
R E FE R E N C E S
 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 
Global cancer statistics 2018: GLOBOCAN estimates of incidence 
and mortality worldwide for 36 cancers in 185 countries. CA Cancer 
J Clin. 2018;68(6):394- 424.
 2. Arnold D, Lueza B, Douillard JY, et al. Prognostic and predic-
tive value of primary tumour side in patients with RAS wild- type 
metastatic colorectal cancer treated with chemotherapy and 
EGFR directed antibodies in six randomized trials. Annal Oncol. 
2017;28(8):1713- 1729.
 3. Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and predictive 
relevance of primary Tumor location in patients with RAS wild- 
type metastatic colorectal cancer: retrospective analyses of the 
CRYSTAL and FIRE- 3 Trials. JAMA Oncol. 2017;3(2):194- 201.
 4. Le DT, Kim TW, Van Cutsem E, et al. Phase II open- label study of 
pembrolizumab in treatment- refractory, microsatellite instability- 
high/mismatch repair- deficient metastatic colorectal cancer: 
KEYNOTE- 164. J Clin Onco. 2020;38(1):11- 19.
 5. Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, Binimetinib, and 
Cetuximab in BRAF V600E- mutated colorectal cancer. N Engl J Med. 
2019;381(17):1632- 1643.
 6. Ceelen W, Van Nieuwenhove Y, Pattyn P. Prognostic value of the 
lymph node ratio in stage III colorectal cancer: a systematic review. 
Ann Surg Oncol. 2010;17(11):2847- 2855.
 7. Willaert W, Mareel M, Van De Putte D, Van Nieuwenhove Y, 
Pattyn P, Ceelen W. Lymphatic spread, nodal count and the ex-
tent of lymphadenectomy in cancer of the colon. Cancer Treat Rev. 
2014;40(3):405- 413.
 8. Kataoka K, Ysebaert H, Shiozawa M, et al. Prognostic significance 
of number versus location of positive mesenteric nodes in stage iii 
colon cancer. Eur J Surg Oncol. 2019;45(10):1862- 1869.
 9. Kataoka K, Beppu N, Shiozawa M, et al. Colorectal cancer treated 
by resection and extended lymphadenectomy: patterns of spread in 
left- and right- sided tumours. Br J Surg. 2020;107(8):1070- 1078.
 10. Taieb J, Le Malicot K, Shi Q, et al. Prognostic value of BRAF and 
KRAS mutations in MSI and MSS Stage III colon cancer. J Natl 
Cancer Inst. 2017;109(5).
 11. Taieb J, Kourie HR, Emile JF, et al. Association of Prognostic Value 
of Primary Tumor Location in Stage III Colon Cancer With RAS and 
BRAF Mutational Status. JAMA Oncol. 2018;4(7):e173695.
 12. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of 
malignant tumours. New York: John Wiley & Sons; 2011.
 13. Søndenaa K, Quirke P, Hohenberger W, et al. The rationale behind 
complete mesocolic excision (CME) and a central vascular liga-
tion for colon cancer in open and laparoscopic surgery : proceed-
ings of a consensus conference. Int J Colorectal Dis. 2014;29(4): 
419- 428.
 14. Hohenberger W, Weber K, Matzel K, Papadopoulos T, Merkel S. 
Standardized surgery for colonic cancer: complete mesocolic exci-
sion and central ligation– technical notes and outcome. Colorectal 
Dis. 2009;11(4):354- 364; discussion 364– 355.
 15. Suraweera N, Duval A, Reperant M, et al. Evaluation of tumor mi-
crosatellite instability using five quasimonomorphic mononucle-
otide repeats and pentaplex PCR. Gastroenterology. 2002;123(6): 
1804- 1811.
 16. Watanabe T, Muro K, Ajioka Y, et al. Japanese Society for Cancer of 
the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of 
colorectal cancer. Int J Clin Oncol. 2018;23(1):1- 34.
 17. Wasserstein RL, Schirm AL, Lazar NA. Moving to a World Beyond “p 
< 0.05”. Am Statistic. 2019;73(sup1):1- 19.
 18. Halsted WSI. The Results of Operations for the Cure of Cancer of 
the Breast Performed at the Johns Hopkins Hospital from June, 
1889, to January, 1894. Ann Surg. 1894;20(5):497- 555.
 19. Fisher B. Biological research in the evolution of cancer surgery: a 
personal perspective. Can Res. 2008;68(24):10007- 10020.
 20. Naxerova K, Reiter JG, Brachtel E, et al. Origins of lymphatic 
and distant metastases in human colorectal cancer. Science. 
2017;357(6346):55- 60.
 21. Ulintz PJ, Greenson JK, Wu R, Fearon ER, Hardiman KM. Lymph 
Node Metastases in Colon Cancer Are Polyclonal. Clin Cancer Res. 
2018;24(9):2214- 2224.
 22. Wei Q, Ye Z, Zhong X, et al. Multiregion whole- exome sequencing 
of matched primary and metastatic tumors revealed genomic het-
erogeneity and suggested polyclonal seeding in colorectal cancer 
metastasis. Annal Oncol. 2017;28(9):2135- 2141.
 23. Huh JW, Kim YJ, Kim HR. Distribution of lymph node metastases is 
an independent predictor of survival for sigmoid colon and rectal 
cancer. Ann Surg. 2012;255(1):70- 78.
 24. Ogino S, Nosho K, Irahara N, et al. Lymphocytic reaction to colorec-
tal cancer is associated with longer survival, independent of lymph 
node count, microsatellite instability, and CpG island methylator 
phenotype. Clin Cancer Res. 2009;15(20):6412- 6420.
 25. Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor- infiltrating lympho-
cytes are a marker for microsatellite instability in colorectal carci-
noma. Cancer. 2001;91(12):2417- 2422.
 26. Phillips SM, Banerjea A, Feakins R, Li SR, Bustin SA, Dorudi S. 
Tumour- infiltrating lymphocytes in colorectal cancer with mi-
crosatellite instability are activated and cytotoxic. Br J Surg. 
2004;91(4):469- 475.
 27. Jass JR, Do KA, Simms LA, et al. Morphology of sporadic colorectal 
cancer with DNA replication errors. Gut. 1998;42(5):673- 679.
 28. Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR. 
Histopathological identification of colon cancer with microsatellite 
instability. Am J Pathol. 2001;158(2):527- 535.
 29. Tougeron D, Fauquembergue E, Rouquette A, et al. Tumor- 
infiltrating lymphocytes in colorectal cancers with microsatellite in-
stability are correlated with the number and spectrum of frameshift 
mutations. Modern Pathol. 2009;22(9):1186- 1195.
 30. Speetjens FM, Lauwen MM, Franken KL, et al. Prediction of the im-
munogenic potential of frameshift- mutated antigens in microsatel-
lite instable cancer. Int J Cancer. 2008;123(4):838- 845.
 31. Bombery M, Smith LB, Owens SR. Lymph Node Size and Histology 
Differs in Microsatellite Unstable and Microsatellite Stable Colon 
Cancers. Gastroenterology. 2013;144(5):S882.
 32. Belt EJ, te Velde EA, Krijgsman O, et al. High lymph node yield is 
related to microsatellite instability in colon cancer. Ann Surg Oncol. 
2012;19(4):1222- 1230.
 33. Ishihara S, Murono K, Sasaki K, et al. Impact of Primary Tumor 
Location on Postoperative Recurrence and Subsequent Prognosis 
in Nonmetastatic Colon Cancers: A Multicenter Retrospective 
Study Using a Propensity Score Analysis. Ann Surg. 2018;267(5): 
917- 921.
 34. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular 
subtypes of colorectal cancer. Nat Med. 2015;21(11):1350- 1356.
 35. Aderka D, Stintzing S, Heinemann V. Explaining the unexplainable: 
discrepancies in results from the CALGB/SWOG 80405 and FIRE- 3 
studies. Lancet Oncol. 2019;20(5):e274- e283.
 36. Alwers E, Jansen L, Bläker H, et al. Microsatellite instability and 
survival after adjuvant chemotherapy among stage II and III colon 
cancer patients: results from a population- based study. Mol Oncol. 
2020;14(2):363- 372.
 37. Zaanan A, Shi Q, Taieb J, et al. Role of Deficient DNA Mismatch 
Repair Status in Patients With Stage III Colon Cancer Treated 
With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 
Randomized Clinical Trials. JAMA Oncol. 2018;4(3):379- 383.
     |  11JIHYUNG et al
 38. Grothey A, Sobrero AF, Shields AF, et al. Duration of Adjuvant 
Chemotherapy for Stage III Colon Cancer. N Engl J Med. 
2018;378(13):1177- 1188.
 39. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair 
as a predictive marker for lack of efficacy of fluorouracil- based adju-
vant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219- 3226.
 40. Yamamoto H, Murata K, Fukunaga M, et al. Micrometastasis 
Volume in Lymph Nodes Determines Disease Recurrence Rate of 
Stage II Colorectal Cancer: A Prospective Multicenter Trial. Clinic 
Cancer Res. 2016;22(13):3201- 3208.
 41. Vogelaar FJ, Reimers MS, van der Linden RL, et al. The diag-
nostic value of one- step nucleic acid amplification (OSNA) for 
sentinel lymph nodes in colon cancer patients. Ann Surg Oncol. 
2014;21(12):3924- 3930.
How to cite this article: Song J, Kataoka K, Yamada T, et al. 
The impact of molecular profile on the lymphatic spread 
pattern in stage III colon cancer. Cancer Sci. 2021;00:1– 11. 
https://doi.org/10.1111/cas.14819
